Hoffmann-La Roche Matches Revenue Expectations Despite Pharma Sales Dip
- Reports
- 3
- Developments
- 1
- Repetition
- 67%
New informationRepeats or wire copies
What happened
FactSet released the latest sales figures for Hoffmann-La Roche. The company matched Wall Street's revenue expectations and reaffirmed its guidance for the year. Ocrevus, Hoffmann-La Roche's largest revenue generator, produced $2.25 billion in third-quarter sales, which was in line with forecasts. However, overall pharmaceutical sales totaled $14.85 billion, missing the $14.9 billion estimate.
From investors.com
Why it matters
Hoffmann-La Roche's ability to meet revenue expectations allowed the company to maintain its guidance despite a shortfall in overall pharmaceutical sales. The strong performance of Ocrevus, its biggest moneymaker, was consistent with market predictions.
From investors.com
Who's involved
- FactSetAmerican financial data company that reported the sales figures
- Hoffmann-La RocheSwiss healthcare company whose third-quarter sales were reported
Keep exploring
The entities involved
-
FactSet
American financial data company
-
Hoffmann-La Roche
Swiss healthcare company
Nothing else this week.